Do you know the right strategies in the pharmaceutical manufacturing sector?

Strategies, security and software for a better process:

A lot of news in the pharmaceutical manufacturing sector creates a dire scenario. With a lack of products in the pipeline and a continuing patent cliff staring companies in the face, they also face rising costs in development and production. They need strategies to streamline processes, find the most promising new products and accurately move them through a regulatory morass.

To read the entire article click here.

Learn more at our next conference for a  business transformation approach:  
International Conference PLM in Pharmaceutical & Biotechnical Development
http://bit.ly/MriGOv

Product Lifecycle Management in Life Sciences Industry - Evolving from detached to cross-functional management

By combining product and process data PLM provides visibility and traceablity as well as the link between the regulatory and manufacturing world.

In the experience of Deloitte, the traditional functional PLM organisation of a Life Sciences company suffers from virtual walls between the functional silos, product and process data being separated making it difficult for cross-functional information to flow quickly and securely.

Gain insight and download here the complete article:

http://bit.ly/KJpzBk

PLM in Sanofi: Safer Projects & Accelerated Timelines for Development

In this interview Philippe Lienard, Head of the Early Development Unit at Sanofi explains the approach they have taken in the anticipation method for chemical stability which has resulted in safer projects and accelerated the timeline for development.

Product lifecycle management is a holistic approach to emerging product and process knowledge that spans the stages of a product from conception through to commercialisation, thus improving the manufacturing process and quality of products.

Pharma IQ: Philippe, could you describe what’s happening in the industry currently around the whole latest product lifecycle management strategies and how this can be used to optimise product development processes? 

P Lienard: So to optimise the product development process we are particularly involved in some in-silico approach to assess the properties of the candidate to enter in development, and the benefit of this will be to anticipate any potential issues regarding, for example, chemical stability, solubility, crystalinity, whatever property will be very key for the drug development.
 

Pharma IQ: What strategies do you use at Sanofi to design and create safer products?

P Lienard: So the strategy is to test the compound on several animal models and for this we have to address a formulation for animals. Generally, those formulations are designed to anticipate the clinic formulation and so it allows us to determine the safe dose, the maximum tolerated dose, and it’s a good starting point for the first treatment.

Continue reading the  interview here.

Learn more at our next conference for a  business transformation approach:  
International Conference PLM in Pharmaceutical & Biotechnical Development
http://bit.ly/MriGOv